The Underweight rating suggests that Barclays analysts believe Illumina's stock may underperform the market or its sector. However, the increase in the price target from $50 to $80 indicates that the expected downside may be less severe than previously thought. This could lead to a short-term negative impact on the stock as the market digests the mixed signals of a maintained Underweight rating with a higher price target.